Xanthine Dehydrogenase and Its Role in Cancer Chemotherapy
Xanthine dehydrogenase (EC 18.104.22.168) is a molybdenum iron-sulfur, flavin hydroxylase whose physiological role is ascribed to purine catabolism. Its ready conversion to its oxidase counterpart, xanthine oxidase (EC 22.214.171.124), under normal isolation conditions has complicated studies of this enzyme in the past. Many studies in the past have looked at the role of xanthine oxidase in the metabolism of chemotherapeutic agents requiring bioreductive activation for their antineoplastic activities. This paper reviews some of xanthine dehydrogenase’s biological and physiological parameters as well as recent studies into the xanthine dehydrogenase-induced activation of bioreductive agents. Studies are also presented that point out this enzyme’s potential role in mitomycin C-induced cytotoxicity to EMT6 cells under aerobic and hypoxic conditions. The potential importance of xanthine dehydrogenase as an enzyme targeted in chemotherapeutic regimens is discussed.
Document Type: Commentary
Publication date: January 1, 1994
Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.
From Volume 23, Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics is Open Access under the terms of the Creative Commons CC BY-NC-ND license.